# Embla

> Embla is a Danish-founded digital health company selling a managed weight and cardiometabolic care benefit to self-funded U.S. employers and health plans. Its programs combine psychology-led coaching, a mobile care platform, clinician-supervised low-dose GLP-1 treatment when appropriate, and structured tapering. The company argues that better support around medication can preserve weight-loss outcomes while reducing pharmacy use, an argument backed by its observational TRIM study of 2,694 members but not yet by a randomized comparison of Embla against conventional care.

- **Founded:** 2021
- **Headquarters:** Georgetown, United States (U.S. headquarters); Copenhagen, Denmark (founded and registered)
- **Founders:** Laust Wilster Axelsen (Co-founder and Co-CEO), Nicholas Syhler (Co-founder and Co-CEO; cardiologist)
- **Team size:** 51-200 employees on LinkedIn; third-party datasets place the team near 50-60.
- **Products:** EmblaThrive, EmblaThriveMD, Embla Embrace, Embla app, Employer and health-plan platform
- **Notable:** Supported more than 30,000 people, according to the company., Published the 2,694-participant TRIM real-world study in Diabetes, Obesity and Metabolism in 2025., Reported 16.7% average weight loss at 64 weeks with an average weekly semaglutide dose of about 1.08 mg in TRIM.

## Products & services

- **EmblaThrive** — Medication-free ACT-based coaching for weight, habits, mental health and cardiometabolic risk.
- **EmblaThriveMD** — Behavioral coaching plus clinician-supervised, personalized low-dose GLP-1 treatment and structured tapering for eligible members.
- **Embla Embrace** — Ongoing coaching and accountability intended to maintain weight loss, reinforce habits and reduce regression.
- **Embla app** — Mobile platform for coach chat and video visits, health and meal logging, medication tracking, courses, communities, recipes, goals, recaps and connected-health data.
- **Employer and health-plan platform** — A fully managed cardiometabolic benefit with implementation, clinical operations, engagement tools and reporting for benefits buyers.

## Achievements

- Supported more than 30,000 people, according to the company.
- Published the 2,694-participant TRIM real-world study in Diabetes, Obesity and Metabolism in 2025.
- Reported 16.7% average weight loss at 64 weeks with an average weekly semaglutide dose of about 1.08 mg in TRIM.
- Reported that 78.5% of the relevant TRIM cohort tapered or stopped GLP-1 treatment without average weight regain after tapering.
- Expanded from Denmark and the United Kingdom into the U.S. employer-benefits market.
- Raised €10 million in Series A funding in August 2023.

## Latest updates

- **2026-06** — The Android app was updated with expanded tracking, coaching and program support; Google Play lists more than 1,000 downloads.
- **2026-04** — Embla said it had supported more than 30,000 people and positioned its U.S. offering as a fully managed cardiometabolic benefit.
- **2026-02** — The company published new employer-facing explainers on low-dose GLP-1 use and coaching-based wellness programs.
- **2025-09** — The TRIM real-world analysis was published in Diabetes, Obesity and Metabolism.
- **2025-04** — Avant Health publicly announced its partnership with Embla for U.S. employer clients.

## Links

- Website: https://www.joinembla.com
- LinkedIn: https://www.linkedin.com/company/join-embla
- Instagram: https://www.instagram.com/joinembla
- Facebook: https://www.facebook.com/joinembla

---

Profile page: https://yespress.io/embla
Published by YesPress — https://yespress.io
Last updated: 2026-08-21